GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSX) » Definitions » Equity-to-Asset

BSX (Boston Scientific) Equity-to-Asset : 0.54 (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Boston Scientific Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Boston Scientific's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $20,708 Mil. Boston Scientific's Total Assets for the quarter that ended in Sep. 2024 was $38,078 Mil. Therefore, Boston Scientific's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.54.

The historical rank and industry rank for Boston Scientific's Equity-to-Asset or its related term are showing as below:

BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35   Med: 0.43   Max: 0.56
Current: 0.54

During the past 13 years, the highest Equity to Asset Ratio of Boston Scientific was 0.56. The lowest was 0.35. And the median was 0.43.

BSX's Equity-to-Asset is ranked worse than
60.48% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: 0.64 vs BSX: 0.54

Boston Scientific Equity-to-Asset Historical Data

The historical data trend for Boston Scientific's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Equity-to-Asset Chart

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.50 0.52 0.54 0.55

Boston Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.55 0.54 0.55 0.54

Competitive Comparison of Boston Scientific's Equity-to-Asset

For the Medical Devices subindustry, Boston Scientific's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Equity-to-Asset falls into.



Boston Scientific Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Boston Scientific's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=19281/35136
=0.55

Boston Scientific's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=20708/38078
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific  (NYSE:BSX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Boston Scientific Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Executives
Wendy Carruthers officer: SVP, Human Resources C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Arthur C Butcher officer: SVP&Pres, Endoscopy C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Edward J Ludwig director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
John Bradley Sorenson officer: SVP, Glob Ops & Qual C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Michael F Mahoney officer: President BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Joseph Michael Fitzgerald officer: SVP & President, Endovascular C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Jeffrey B. Mirviss officer: SVP&Pres, Periph Intervent C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel J. Brennan officer: EVP and CFO BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Vance R Brown officer: SVP, GC and Corp. Secretary C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Thepaut Eric Francis Yves officer: SVP & Pres, Europe C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Susan E Morano director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jessica L Mega director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jonathan Monson officer: VP, Corp Controller and CAO C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Nelda J Connors director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234